Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies
Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies - Anivive is the first recipient to be awarded a MUMS grant during this round of funding - Funding will accelerate ongoing canine lymphoma studies - Anivive to initiate studies of verdinexor to treat other types of cancer News provided by Share this article Share this article LONG BEACH, Calif., July 8, 2021 /PRNewswire/ -- Anivive, a pet health technology company transforming the therapeutic discovery and development process, received $500,000 in grant funding to continue research on the use of LAVERDIA™ -CA1 (verdinexor)...
Source: prnewswire.com